VERZONI, ELENA

VERZONI, ELENA  

Universita' degli Studi di MILANO  

Risultati 1 - 17 di 17 (tempo di esecuzione: 0.106 secondi).
Titolo Data di pubblicazione Autore(i) Tipo File Abstract
Biomarker-driven immunotherapy for precision medicine in prostate cancer 1-gen-2022 Ottini A.Sepe P.Beninato T.Verzoni E.Giannatempo P.De Braud F.Procopio G. + Article (author) -
Cabozantinib in the treatment of advanced renal cell carcinoma : Design, development, and potential place in the therapy 1-gen-2016 E. VerzoniA. MennittoF. de Braud + Article (author) -
Clinical impact of Pancreatic metastases from renal cell carcinoma : A multicenter retrospective analysis 1-apr-2016 E. VerzoniV. MazzaferroF. De Braud + Article (author) -
Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma? 1-set-2017 E. VerzoniM. PrisciandaroA. MennittoF. de Braud + Article (author) -
Everolimus and temsirolimus are not the same second-line in metastatic renal cell carcinoma : a systematic review and meta-analysis of literature data 1-apr-2015 E. VerzoniI. TestaF. De Braud + Article (author) -
First line treatment of metastatic renal cell carcinoma : two standards with different toxicity profile 1-gen-2014 E. VerzoniF. De Braud + Article (author) -
Immunotherapy advances in uro-genital malignancies 1-set-2016 D. RaggiE. VerzoniA. NecchiF. de Braud + Article (author) -
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer : a systematic review and meta-analysis 1-gen-2015 E. VerzoniF. de Braud + Article (author) -
Patient approach in advanced/metastatic renal cell carcinoma : focus on the elderly population and treatment-related toxicity 1-nov-2013 E. VerzoniF. de BraudI. Testa + Article (author) -
Prognostic reclassification of patients with intermediate-risk metastatic germ cell tumors : implications for clinical practice, trial design, and molecular interrogation 1-lug-2015 D. RaggiP. GiannatempoE. VerzoniF. De BraudA. Necchi + Article (author) -
Rationale and protocol of RESORT, a randomized, open-label, multicenter phase II study to evaluate the efficacy of sorafenib in patients with advanced renal cell carcinoma after radical resection of the metastases 1-gen-2014 E. VerzoniP. BiondaniI. TestaF. de Braud + Article (author) -
Rationale and protocol of SOAP : A phase II study to evaluate the efficacy of Sorafenib as second-line treatment after pazopanib in patients with advanced renal cell carcinoma 1-dic-2014 E. VerzoniF. De Braud + Article (author) -
Safety of abiraterone acetate in castration-resistant prostate cancer patients with concomitant cardiovascular risk factors 1-ott-2015 I. TestaE. VerzoniR. ValdagniF. De Braud + Article (author) -
Safety profile and treatment response of everolimus in different solid tumors : an observational study 1-gen-2014 E. VerzoniS. PuscedduP. BiondaniI. TestaF. Debraud + Article (author) -
Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib 1-apr-2015 E. VerzoniF. De Braud + Article (author) -
Study design and clinical evidence in mRCC : can we save axitinib as a first-line therapy? 1-mag-2014 E. VerzoniF. De Braud + Article (author) -
Treatment of elderly patients with metastatic renal cell carcinoma 1-gen-2016 E. VerzoniC. MaggiF. De Braud + Article (author) -